Literature DB >> 17339493

Costimulation blockade inhibits allergic sensitization but does not affect established allergy in a murine model of grass pollen allergy.

Birgit Linhart1, Sinda Bigenzahn, Arnulf Hartl, Christian Lupinek, Josef Thalhamer, Rudolf Valenta, Thomas Wekerle.   

Abstract

Type I allergy is characterized by the development of an initial Th2-dependent allergen-specific IgE response, which is boosted upon a subsequent allergen encounter. Although the immediate symptoms of allergy are mainly IgE-mediated, allergen-specific T cell responses contribute to the late phase as well as to the chronic manifestations of allergy. This study investigates the potential of costimulation blockade with CTLA4Ig and an anti-CD154 mAb for modifying the allergic immune response to the major timothy grass pollen allergen Phl p 5 in a mouse model. BALB/c mice were treated with the costimulation blockers at the time of primary sensitization to the Phl p 5 allergen or at the time of a secondary allergen challenge. Costimulation blockade (CTLA4Ig plus anti-CD154 or anti-CD154 alone) at the time of sensitization prevented the development of allergen-specific IgE, IgM, IgG, and IgA responses compared with untreated but sensitized mice. However, costimulation blockade had no influence on established IgE responses in sensitized mice. Immediate-type reactions as analyzed by a rat basophil leukemia cell mediator release assay were only suppressed by early treatment but not by a costimulation blockade after sensitization. CTLA4Ig given alone failed to suppress both the primary and the secondary allergen-specific Ab responses. Allergen-specific T cell activation was suppressed in mice by early as well as by a late costimulation blockade, suggesting that IgE responses in sensitized mice are independent of T cell help. Our results indicate that T cell suppression alone without active immune regulation or a shifting of the Th2/Th1 balance is not sufficient for the treatment of established IgE responses in an allergy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17339493      PMCID: PMC2993922          DOI: 10.4049/jimmunol.178.6.3924

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  50 in total

1.  Costimulatory signal blockade in murine relapsing experimental autoimmune encephalomyelitis.

Authors:  M Schaub; S Issazadeh; T H Stadlbauer; R Peach; M H Sayegh; S J Khoury
Journal:  J Neuroimmunol       Date:  1999-05-03       Impact factor: 3.478

2.  CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris.

Authors:  J R Abrams; M G Lebwohl; C A Guzzo; B V Jegasothy; M T Goldfarb; B S Goffe; A Menter; N J Lowe; G Krueger; M J Brown; R S Weiner; M J Birkhofer; G L Warner; K K Berry; P S Linsley; J G Krueger; H D Ochs; S L Kelley; S Kang
Journal:  J Clin Invest       Date:  1999-05       Impact factor: 14.808

Review 3.  Sensitization to airborne environmental allergens: unresolved issues.

Authors:  P G Holt; W R Thomas
Journal:  Nat Immunol       Date:  2005-10       Impact factor: 25.606

Review 4.  Peptide-based therapeutic vaccines for allergic and autoimmune diseases.

Authors:  Mark Larché; David C Wraith
Journal:  Nat Med       Date:  2005-04       Impact factor: 53.440

5.  Costimulation through CD86 is involved in airway antigen-presenting cell and T cell responses to allergen in atopic asthmatics.

Authors:  M Larché; S J Till; B M Haselden; J North; J Barkans; C J Corrigan; A B Kay; D S Robinson
Journal:  J Immunol       Date:  1998-12-01       Impact factor: 5.422

6.  Natural course of sensitization to food and inhalant allergens during the first 6 years of life.

Authors:  M Kulig; R Bergmann; U Klettke; V Wahn; U Tacke; U Wahn
Journal:  J Allergy Clin Immunol       Date:  1999-06       Impact factor: 10.793

7.  The role of non-deletional tolerance mechanisms in a murine model of mixed chimerism with costimulation blockade.

Authors:  Sinda Bigenzahn; Peter Blaha; Zvonimir Koporc; Ines Pree; Edgar Selzer; Helga Bergmeister; Friedrich Wrba; Christoph Heusser; Kathrin Wagner; Ferdinand Muehlbacher; Thomas Wekerle
Journal:  Am J Transplant       Date:  2005-06       Impact factor: 8.086

8.  Costimulation blockade with belatacept in renal transplantation.

Authors:  Flavio Vincenti; Christian Larsen; Antoine Durrbach; Thomas Wekerle; Björn Nashan; Gilles Blancho; Philippe Lang; Josep Grinyo; Philip F Halloran; Kim Solez; David Hagerty; Elliott Levy; Wenjiong Zhou; Kannan Natarajan; Bernard Charpentier
Journal:  N Engl J Med       Date:  2005-08-25       Impact factor: 91.245

9.  Nasal provocation with allergen induces a secondary serum IgE antibody response.

Authors:  R M Naclerio; N F Adkinson; B Moylan; F M Baroody; D Proud; A Kagey-Sobotka; L M Lichtenstein; R Hamilton
Journal:  J Allergy Clin Immunol       Date:  1997-10       Impact factor: 10.793

10.  Immunization with purified natural and recombinant allergens induces mouse IgG1 antibodies that recognize similar epitopes as human IgE and inhibit the human IgE-allergen interaction and allergen-induced basophil degranulation.

Authors:  S Vrtala; T Ball; S Spitzauer; B Pandjaitan; C Suphioglu; B Knox; W R Sperr; P Valent; D Kraft; R Valenta
Journal:  J Immunol       Date:  1998-06-15       Impact factor: 5.422

View more
  28 in total

1.  Tolerization of a type I allergic immune response through transplantation of genetically modified hematopoietic stem cells.

Authors:  Ulrike Baranyi; Birgit Linhart; Nina Pilat; Martina Gattringer; Jessamyn Bagley; Ferdinand Muehlbacher; John Iacomini; Rudolf Valenta; Thomas Wekerle
Journal:  J Immunol       Date:  2008-06-15       Impact factor: 5.422

Review 2.  The pathologic and clinical intersection of atopic and autoimmune disease.

Authors:  Ankoor Shah
Journal:  Curr Allergy Asthma Rep       Date:  2012-12       Impact factor: 4.806

Review 3.  The role of costimulatory molecules in allergic disease and asthma.

Authors:  Vincent Lombardi; Abinav K Singh; Omid Akbari
Journal:  Int Arch Allergy Immunol       Date:  2009-09-29       Impact factor: 2.749

Review 4.  Re-educating immunity in respiratory allergies: the potential for hematopoietic stem cell-mediated gene therapy.

Authors:  Jeremy F Brooks; Janet M Davies; James W Wells; Raymond J Steptoe
Journal:  J Mol Med (Berl)       Date:  2017-11-17       Impact factor: 4.599

5.  Persistent molecular microchimerism induces long-term tolerance towards a clinically relevant respiratory allergen.

Authors:  U Baranyi; N Pilat; M Gattringer; B Linhart; C Klaus; E Schwaiger; J Iacomini; R Valenta; T Wekerle
Journal:  Clin Exp Allergy       Date:  2012-08       Impact factor: 5.018

6.  A hypoallergenic cat vaccine based on Fel d 1-derived peptides fused to hepatitis B PreS.

Authors:  Katarzyna Niespodziana; Margarete Focke-Tejkl; Birgit Linhart; Vera Civaj; Katharina Blatt; Peter Valent; Marianne van Hage; Hans Grönlund; Rudolf Valenta
Journal:  J Allergy Clin Immunol       Date:  2011-03-16       Impact factor: 10.793

7.  Anti-OX40L alone or in combination with anti-CD40L and CTLA4Ig does not inhibit the humoral and cellular response to a major grass pollen allergen.

Authors:  M Gattringer; U Baranyi; N Pilat; K Hock; C Klaus; H E Ramsey; F Wrba; R Valenta; T Wekerle
Journal:  Clin Exp Allergy       Date:  2016-02       Impact factor: 5.018

8.  Regulatory T cells and the control of the allergic response.

Authors:  Ana Agua-Doce; Luis Graca
Journal:  J Allergy (Cairo)       Date:  2012-09-29

9.  CTLA4-Ig immunosuppressive activity at the level of dendritic cell/T cell crosstalk.

Authors:  Edda Mayer; Markus Hölzl; Sarah Ahmadi; Barbara Dillinger; Nina Pilat; Dietmar Fuchs; Thomas Wekerle; Andreas Heitger
Journal:  Int Immunopharmacol       Date:  2013-02-20       Impact factor: 4.932

10.  Engraftment of retrovirally transduced Bet v 1-GFP expressing bone marrow cells leads to allergen-specific tolerance.

Authors:  Martina Gattringer; Ulrike Baranyi; Nina Pilat; Karin Hock; Christoph Klaus; Elisabeth Buchberger; Haley Ramsey; John Iacomini; Rudolf Valenta; Thomas Wekerle
Journal:  Immunobiology       Date:  2013-03-30       Impact factor: 3.144

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.